• The novel composite material, incorporating heparin, PEG, and a zwitterionic polymer, significantly reduces platelet adhesion and activation, improving hemocompatibility.
• The modified surface prolongs activated partial thromboplastin time (aPTT), indicating enhanced anticoagulant activity.
• The composite promotes endothelial cell adhesion and proliferation, demonstrating superior biocompatibility for vascular applications.
• The synergistic effect of heparin, PEG, and zwitterionic modification offers a promising strategy for developing blood-contacting medical devices.